secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001213900-23-047460
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics annual meeting: all proposals approved by shareholders
---------------------------------------------------------------------------

- Class III directors elected: Shefferman 5.68M for, Flannelly 5.63M, Smith 5.66M; 2.26M broker non-votes each.
- Ratification of Ernst & Young as auditor passed: 8.16M for, 29,326 against, 709 abstentions.
- Advisory vote on named executive officer compensation approved: 5.57M for, 296,338 against, 62,576 abstentions.
- Record date April 11, 2023; 11,307,962 shares outstanding and entitled to vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023047460/0001213900-23-047460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023047460/ea179944-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-047460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer